Loading patent…
AssigneeZealand Pharma A/S
InventorsJørgen Søberg Petersen, Anne Louise Kjoelbye, Marie Skovgaard, Henrik Duelund Pedersen, Lene Axelsen, Ditte Riber, Eddi Meier, Rie Schultz Hansen, Keld Fosgerau, Bjarne Due Larsen
Estimating the term…
The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.
A method of treating heart disease or heart dysfunction in a subject, comprising administering a glucagon-GLP-1 dual agonist to the subject as a positive inotropic agent.
3-4. (canceled)
7-29. (canceled)
31-40. (canceled)
42-45. (canceled)
47-53. (canceled)
56-118. (canceled)
121-122. (canceled)
124-133. (canceled)
136-154. (canceled)
Dependencies are inferred from the claim text.